Take Homes in Lung Cancer

MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK-positive non-small cell lung cancer, which were presented at ESMO Congress, in a video interview with Healio.

MADRID — Healio spoke with Hossein Borghaei, DO, MS, about the results of the MARIPOSA-2 trial, which were presented at ESMO Congress.

MADRID — In this video interview with Healio, Hossein Borghaei, DO, MS, talked about results from the MARIPOSA study presented at ESMO Congress.

MADRID — Hossein Borghaei, DO, MS, discussed results from the PAPILLON trial, which combined amivantamab and chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated non-small cell lung cancer, in a video interview.

MADRID — Amivantamab plus chemotherapy improved PFS, objective response rate and intracranial PFS compared with chemotherapy alone in patients with EGFR-mutated advanced non-small cell lung cancer after progression on osimertinib.

MADRID — Pasi Jänne, MD, PhD, discussed the “encouraging” clinical activity of adagrasib with pembrolizumab in patients with KRAS G12C-mutated advanced non-small cell lung cancer in a video interview with Healio at ESMO Congress.

MADRID — In this video, Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discussed MARIPOSA data on amivantamab in EGFR-mutated advanced lung cancer presented at ESMO Congress.

MADRID — There were “many exciting updates in EGFR” in the advanced-stage lung cancer setting at ESMO Congress, according to Julia Rotow, MD.

MADRID — In a video interview, Julia Rotow, MD, discussed positive data from the ALINA study in ALK-positive non-small cell lung cancer presented at ESMO Congress.

MADRID — In this video, Julia Rotow, MD, highlighted positive OS data from the KEYNOTE-671 study of a perioperative pembrolizumab regimen for early-stage non-small-cell lung cancer presented at ESMO Congress.